EVALUATION OF BREAST CANCER RISK WITH SUPPLEMENTARY ULTRASONOGRAPHY TO CHARACTERIZE PALPABLE LUMPS IN MAMMOGRAPHICALLY DENSE BREASTS

56 Background: Mammographic breast density is a significant risk factor for breast cancer. Women with extremely dense breasts are at 4-to-6 times the risk of developing breast cancer than women with primarily fatty breast tissue. Electrical Breast Densitometry (EBD) is a new technique that assesses breast density. EBD is non-ionizing, fast, has low cost per test ($20-$30) and may help in breast cancer risk assessment in the primary care setting. Methods: This study evaluated the feasibility of the EBD in an IRB-approved pilot study of 20 patients. The study used a custom-made self-adhesive electrode (SenoSENSE Medical Systems, Toronto, Canada) interfaced to an off-the-shelf impedance meter (Bodystat 1500, Bodystat, Isle of Man, UK) with a customized cable. On the same day as the subject’s scheduled mammogram, impedance measurements were acquired for each breast. Mammogram densities were scored by a trained radiologist using standard BiRADS breast density categories 1 to 4. Results: A high correlation coefficient was observed (Pearson correlation coefficient >0.80) between breast density determined by the EBD and the BiRADS breast density score. In addition a statistically significant difference was observed between dense categories (BiRADS 3,4) and fatty categories (BiRADS 1,2) (p<0.01), as well as between extremely dense breasts (BiRADS 4) and all other categories (p<0.01). Very high correlation (Pearson correlation coefficient >0.95) was observed between EBD measurements on the left and right breasts. Previous studies have reported a left/right correlation of 0.89 for blinded mammography readers. Conclusions: These results suggests that the EBD measure may be less variable than mammographic estimates of density. The results of the study suggest that Electrical Breast Densitometry is a promising technique for the assessment of breast density and the ability to aid in evaluation of breast cancer risk. It can be reasonably deployed at primary care facilities.

Download Full-text

Women with Dense Breasts Have Higher Breast Cancer Risk

The Nurse Practitioner ◽

10.1097/01.npr.0000263082.63277.09 ◽

2007 ◽

Vol 32 (3) ◽

pp. 26,29

Author(s):

&NA;

Keyword(s):

Breast Cancer ◽

Breast Cancer Risk ◽

Cancer Risk ◽

Dense Breasts

Download Full-text

Dense Breasts Linked to Higher Breast Cancer Risk, But Clinicians Unsure of Application

JNCI Journal of the National Cancer Institute ◽

10.1093/jnci/djm243 ◽

2007 ◽

Vol 99 (22) ◽

pp. 1661-1663 ◽

Cited By ~ 1

Author(s):

R. Twombly

Keyword(s):

Breast Cancer ◽

Breast Cancer Risk ◽

Cancer Risk ◽

Dense Breasts

Download Full-text

MRI versus Mammography plus Ultrasound in Women at Intermediate Breast Cancer Risk: Study Design and Protocol of the MRIB Multicenter, Randomized, Controlled Trial

Diagnostics ◽

10.3390/diagnostics11091635 ◽

2021 ◽

Vol 11 (9) ◽

pp. 1635

Author(s):

Luigina Ada Bonelli ◽

Massimo Calabrese ◽

Paolo Belli ◽

Stefano Corcione ◽

Claudio Losio ◽

...

Keyword(s):

Breast Cancer ◽

Ovarian Cancer ◽

Randomized Controlled Trial ◽

Breast Cancer Risk ◽

Cancer Risk ◽

Controlled Trial ◽

Hormone Replacement ◽

Dense Breasts ◽

Randomized Controlled ◽

Multicenter Randomized Controlled Trial

In women at high/intermediate lifetime risk of breast cancer (BC-LTR), contrast-enhanced magnetic resonance imaging (MRI) added to mammography ± ultrasound (MX ± US) increases sensitivity but decreases specificity. Screening with MRI alone is an alternative and potentially more cost-effective strategy. Here, we describe the study protocol and the characteristics of enrolled patients for MRIB feasibility, multicenter, randomized, controlled trial, which aims to compare MRI alone versus MX+US in women at intermediate breast cancer risk (aged 40–59, with a 15–30% BC-LTR and/or extremely dense breasts). Two screening rounds per woman were planned in ten centers experienced in MRI screening, the primary endpoint being the rate of cancers detected in the 2 arms after 5 years of follow-up. From July 2013 to November 2015, 1254 women (mean age 47 years) were enrolled: 624 were assigned to MX+US and 630 to MRI. Most of them were aged below 50 (72%) and premenopausal (45%), and 52% used oral contraceptives. Among postmenopausal women, 15% had used hormone replacement therapy. Breast and/or ovarian cancer in mothers and/or sisters were reported by 37% of enrolled women, 79% had extremely dense breasts, and 41% had a 15–30% BC-LTR. The distribution of the major determinants of breast cancer risk profiles (breast density and family history of breast and ovarian cancer) of enrolled women varied across centers.

Download Full-text